               SEQUENCE LISTING

<110> Dompè Farmaceutici SpA

<120> NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES

<130> 248EP

<160> 4

<170> BiSSAP 1.3.6

<210> 1
<211> 118
<212> PRT
<213> Homo sapiens


<220> 
<223> Recombinant human NGF

<400> 1
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp 
1               5                   10                  15      
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys 
            20                  25                  30          
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val 
        35                  40                  45              
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val 
    50                  55                  60                  
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys 
65                  70                  75                  80  
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln 
                85                  90                  95      
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu 
            100                 105                 110         
Ser Arg Lys Ala Val Arg 
        115             

<210> 2
<211> 120
<212> PRT
<213> Homo sapiens


<220> 
<223> Recombinant human NGF

<400> 2
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp 
1               5                   10                  15      
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys 
            20                  25                  30          
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val 
        35                  40                  45              
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val 
    50                  55                  60                  
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys 
65                  70                  75                  80  
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln 
                85                  90                  95      
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu 
            100                 105                 110         
Ser Arg Lys Ala Val Arg Arg Ala 
        115                 120 

<210> 3
<211> 117
<212> PRT
<213> Homo sapiens


<220> 
<223> Recombinant human NGF

<400> 3
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp 
1               5                   10                  15      
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys 
            20                  25                  30          
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val 
        35                  40                  45              
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val 
    50                  55                  60                  
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys 
65                  70                  75                  80  
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln 
                85                  90                  95      
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu 
            100                 105                 110         
Ser Arg Lys Ala Val 
        115         

<210> 4
<211> 119
<212> PRT
<213> Homo sapiens


<220> 
<223> Recombinant human NGF

<400> 4
Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys Asp 
1               5                   10                  15      
Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr Asp Ile Lys 
            20                  25                  30          
Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile Asn Asn Ser Val 
        35                  40                  45              
Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg Asp Pro Asn Pro Val 
    50                  55                  60                  
Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys His Trp Asn Ser Tyr Cys 
65                  70                  75                  80  
Thr Thr Thr His Thr Phe Val Lys Ala Leu Thr Met Asp Gly Lys Gln 
                85                  90                  95      
Ala Ala Trp Arg Phe Ile Arg Ile Asp Thr Ala Cys Val Cys Val Leu 
            100                 105                 110         
Ser Arg Lys Ala Val Arg Arg 
        115                 

